Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2024 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $4.75, expectations were $1.13.
Ligand Pharmaceuticals Inc (LGND)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Cardinal Capital Amy Minella | 559,235 | $40,880,091 | +152% | 2.05% |
| 2. | Impax Asset Management Ian Simm | 255,208 | $18,655,705 | +25% | 0.07% |
| 3. | GLG Partners Noam Gottesman | 68,657 | $5,018,827 | -53% | 0.01% |
| 4. | D E Shaw D. E. Shaw | 62,592 | $4,575,475 | -29% | 0% |
| 5. | Fisher Asset Management Ken Fisher | 53,377 | $3,901,858 | +9% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $59.38 | 4,000 | Officer, Director | 73,090 | 2023-09-22 | Filing | |
| $82.76 | 2,500 | Officer | 173,354 | 2022-05-13 | Filing | |
| $82.52 | 1,000 | Director | 28,190 | 2020-11-02 | Filing | |
| $87.01 | 750 | Director | 67,203 | 2019-09-03 | Filing | |
| $86.18 | 500 | Officer | 17,151 | 2019-09-03 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $83.20 | 934 | Director | 5,633 | 2024-05-09 | Filing | |
| $86.65 | 134 | Officer | 23,379 | 2024-05-17 | Filing | |
| $86.67 | 5,022 | Officer | 23,513 | 2024-05-17 | Filing | |
| $86.00 | 2,264 | Officer | 21,618 | 2024-05-16 | Filing | |
| $86.01 | 5,873 | Officer | 23,882 | 2024-05-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,962,314 | $211,568,465 | 0% | |
| 2. | 1,876,514 | $134,020,630 | 0% | |
| 3. | 1,343,154 | $95,928,428 | 0.05% | |
| 4. | 987,354 | $70,517,000 | 0.08% | |
| 5. | 668,284 | $47,728,843 | 0% |
News See All
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2023 Earnings Call Transcript
Ligand Pharmaceuticals Incorporated beats earnings expectations. Reported EPS is $1.03, expectations were $0.58.
13 Most Promising Small-Cap Stocks According to Analysts
In this piece, we will take a look at the 13 most promising small-cap stocks according to analysts.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2023 Earnings Call Transcript
Operator: Thank you for standing by. My name is Danika and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Ligand Third Quarter 2023 Earnings Webcast.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q2 2023 Earnings Call Transcript
Operator: Thank you for standing by. My name is Brian, and I will be your conference operator today. At this time, I would like to welcome everyone to the Ligand Second Quarter 2023 Earnings Webcast.
Top 12 Small-Cap Stocks With Highest Upside Potential
In this piece, we will take a look at the top 12 small-cap stocks with the highest upside potential.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q1 2023 Earnings Call Transcript
Operator: Thank you for standing by. My name is Kyla Baker and I will be your conference operator today.
10 Best Small-Cap Growth Stocks to Buy Now
Every day, countless stocks see their values rise and fall on the market.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q4 2022 Earnings Call Transcript
Operator: Good evening. My name is Rob and I will be your conference operator today. At this time, I would like to welcome everyone to the Ligand Pharmaceuticals Fourth Quarter 2022 Earnings Webcast.
15 Most Volatile Stocks to Buy Now
Even though the United States stock market is inextricably linked to the US economy, there are increased fears that the factors contributing to the decline of both in the past few months are vastly different...